Jonathan Ostrem • UCSF Profiles

Jonathan Ostrem, MD, PhD

Title(s)	Assistant Professor, Medicine
School	School of Medicine
Address	600 16th Street, #N212 San Francisco CA 94158
Phone	415-885-3882
ORCID	0000-0001-9085-1615
vCard	Download vCard

Biography

Education and Training

University of California, San Francisco, CA	PhD	09/2013	Chemical Biology
University of California, San Francisco, CA	MD	06/2016
Brigham and Women's Hospital, Harvard Medical School, MA		06/2018	Internal Medicine
Dana-Farber Cancer Institute, Harvard Medical School, MA		06/2022	Medical Oncology

Awards and Honors

Forbes Magazine	2014	Forbes 30 Under 30: Science & Healthcare
University of California, San Diego	2007	Joseph E. Mayer Award
University of California, San Diego	2007	Phi Beta Kappa
University of California, San Diego	2006	Thomas E. Curtis Scholarship

Overview

Our laboratory uses chemical biology approaches to develop new modes of cancer therapy. We are interested in the design of small molecule and antibody-based cancer therapeutics directed at oncogenic signaling pathways. To accomplish this we use a variety of techniques, including synthetic organic chemistry, biochemistry, protein engineering, and cellular and mouse models of human cancer.

Websites

Ostrem Lab

Research

Research Activities and Funding

Enhancing the precision of targeted therapies for EGFR-mutant lung cancer
Lung Cancer Research Foundation Dec 14, 2022 - Dec 13, 2024
Role: Principal Investigator
Description: Development of a new approach for tumor-specific release of EGFR inhibitors to maximize efficacy while limiting EGFR-related toxicities in patients.

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

Highly specific intracellular ubiquitination of a small molecule. bioRxiv. 2024 Jan 28. Li W, Garcia-Rivera EM, Mitchell DC, Chick JM, Maetani M, Knapp JM, Matthews GM, Shirasaki R, de Matos Simoes R, Viswanathan V, Pulice JL, Rees MG, Roth JA, Gygi SP, Mitsiades CS, Kadoch C, Schreiber SL, Ostrem JML. PMID: 38328167; PMCID: PMC10849632.

View in: PubMed Mentions:
Rational Screening for Cooperativity in Small-Molecule Inducers of Protein-Protein Associations. J Am Chem Soc. 2023 10 25; 145(42):23281-23291. Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL. PMID: 37816014; PMCID: PMC10603787.

View in: PubMed Mentions: 3 Fields:
Che Chemistry
Translation:Cells
Rational screening for cooperativity in small-molecule inducers of protein-protein associations. bioRxiv. 2023 May 24. Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL. PMID: 37292909; PMCID: PMC10245867.

View in: PubMed Mentions:
Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-11. Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC. PMID: 35412860.

View in: PubMed Mentions: 9 Fields:
Neo Neoplasms
Translation:Humans
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016 11; 15(11):771-785. Ostrem JM, Shokat KM. PMID: 27469033.

View in: PubMed Mentions: 254 Fields:
Dru Drug Therapy Pha Pharmacology
Translation:Humans Animals Cells
A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region. Elife. 2014 Oct 01; 3:e03351. Schroeder CM, Ostrem JM, Hertz NT, Vale RD. PMID: 25272277; PMCID: PMC4359372.

View in: PubMed Mentions: 50 Fields:
Bio Biology
Translation:Humans Animals Cells
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A. 2014 Jul 08; 111(27):9983-8. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, Chien HC, Zhang Y, Morrissey KM, Liu J, Ostrem J, Younger NS, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM. PMID: 24961373; PMCID: PMC4103324.

View in: PubMed Mentions: 105 Fields:
Sci Science
Translation:Animals Cells
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28; 503(7477):548-51. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. PMID: 24256730; PMCID: PMC4274051.

View in: PubMed Mentions: 916 Fields:
Sci Science
Translation:Humans Cells